These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 5845288)

  • 1. Plasma concentration of renin in a patient with Conn's syndrome with fibrinoid lesions of the renal arterioles: the effect of treatment with spironolactone.
    Brown JJ; Davies DL; Lever AF; Peart WS; Robertson JI
    J Endocrinol; 1965 Oct; 33(2):279-93. PubMed ID: 5845288
    [No Abstract]   [Full Text] [Related]  

  • 2. Control of plasma aldosterone in a patient with Conn's syndrome before and during spironolactone medication.
    Vetter H; Vetter W
    Klin Wochenschr; 1975 Apr; 53(8):391-3. PubMed ID: 211313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PLASMA RENIN IN A CASE OF CONN'S SYNDROME WITH FIBRINOID LESIONS: USE OF SPINONOLACTONE IN TREATMENT.
    BROWN JJ; DAVIES DL; LEVER AF; PEART WS; ROBERTSON JI
    Br Med J; 1964 Dec; 2(5425):1636-7. PubMed ID: 14213078
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin.
    Brown JJ; Davies DL; Ferriss JB; Fraser R; Haywood E; Lever AF; Robertson JI
    Br Med J; 1972 Jun; 2(5816):729-34. PubMed ID: 4338668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Conn's syndrome. Study of systemic cardiovascular hemodynamics after medical treatment with spironolactone and after surgical treatment].
    Amah G; Blacher J; Girerd X; Kheder A; Ben Maiz H; Safar M
    Presse Med; 1997 Oct; 26(29):1372-7. PubMed ID: 9404344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Spironolactone in essential hypertension associated with abnormal aldosterone regulation and in Conn's syndrome (author's transl)].
    Wambach G; Helber A; Bönner G; Hummerich W; Meurer KA; Kaufmann W
    Dtsch Med Wochenschr; 1980 May; 105(18):647-51. PubMed ID: 7371530
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined captopril and spironolactone treatment in Conn's syndrome with renal impairment and refractory hypertension.
    Atkinson AB; Brown JJ; Davies DL; Lever AF; Robertson JI
    Clin Endocrinol (Oxf); 1981 Jan; 14(1):105-8. PubMed ID: 7014043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An observation of Conn's syndrome. Clinical and biological study].
    Tourniaire J; Revol A; Maret G; Blanc-Brunat N
    Rev Fr Endocrinol Clin; 1968; 9(4):333-50. PubMed ID: 4302797
    [No Abstract]   [Full Text] [Related]  

  • 9. Spironolactone and amiloride in the treatment of low renin hyperaldosteronism and related syndromes.
    Kremer D; Beevers DG; Brown JJ; Davies DL; Ferriss JB; Fraser R; Lever AF; Robertson JI
    Clin Sci Mol Med Suppl; 1973 Aug; 45 Suppl 1():213s-8. PubMed ID: 4361398
    [No Abstract]   [Full Text] [Related]  

  • 10. CONN'S SYNDROME WITH ASSOCIATED PREGNANCY.
    BOUCHER BJ; MASON AS
    Proc R Soc Med; 1965 Aug; 58(8):575-6. PubMed ID: 14341826
    [No Abstract]   [Full Text] [Related]  

  • 11. [A description of a case of Conn's syndrome (author's transl)].
    Martin PL; Dallocchio M; Fourcade JP; Clémenty J; Coqueran J; Choussat A; Bricaud H
    J Radiol Electrol Med Nucl; 1974 May; 55(5):419-22. PubMed ID: 4408421
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of spironolactone in hypertensive patients.
    Crane MG; Harris JJ
    Am J Med Sci; 1970 Dec; 260(6):311-30. PubMed ID: 5511395
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma renin activity in the diagnosis of primary aldosteronism: failure to distinguish primary aldosteronism from essential hypertension.
    Jose A; Kaplan NM
    Arch Intern Med; 1969 Feb; 123(2):141-6. PubMed ID: 5812600
    [No Abstract]   [Full Text] [Related]  

  • 14. [Activity of plasma renin in arterial hypertension with corticoadrenal adenoma. Conn's syndrome].
    Meyer P; Ménard J; Alexandre JM; Druet P; Milliez P
    Prensa Med Argent; 1966; 53(9):710-7. PubMed ID: 6003000
    [No Abstract]   [Full Text] [Related]  

  • 15. [APROPOS OF A CASE OF CONN'S SYNDROME. THE DIFFERENTIAL DIAGNOSIS OF HYPERALDOSTERONISM WITH THE HELP OF DYNAMIC FUNCTION TESTS].
    DUPASQUIER E
    Helv Med Acta; 1964 Nov; 31():426-31. PubMed ID: 14335446
    [No Abstract]   [Full Text] [Related]  

  • 16. [Primary hyperaldosteronism with malignant hypertension].
    Baglin A; Weiss Y; Safar M; Milliez P
    Nouv Presse Med; 1973 Feb; 2(5):295-7. PubMed ID: 4686221
    [No Abstract]   [Full Text] [Related]  

  • 17. Time-related changes in plasma adrenal steroids during treatment with spironolactone in primary aldosteronism.
    Sakamoto H; Ichikawa S; Sakamaki T; Nakamura T; Ono Z; Takayama Y; Murata K
    Am J Hypertens; 1990 Jul; 3(7):533-7. PubMed ID: 2194510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of blood pressure with body and plasma electrolytes in Conn's syndrome.
    Beretta-Piccoli C; Davies DL; Brown JJ; Ferriss B; Fraser R; Lasaridis A; Lever AF; Morton JJ; Robertson JI; Semple PF
    J Hypertens; 1983 Aug; 1(2):197-205. PubMed ID: 6681039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volume-pressure relationships during development of mineralocorticoid hypertension in man.
    Wenting GH; Man in 't Veld AJ; Verhoeven RP; Derkx FH; Schalekamp DH
    Circ Res; 1977 May; 40(5 Suppl 1):I163-70. PubMed ID: 858175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of plasma potassium, renin and aldosterone in the diagnosis of primary hyperaldosteronism; the role of spironolactone in the treatment of this syndrome.
    Brown JJ; Chinn RH; Dusterdieck G; Fraser R; Lever AF; Robertson JI; Tree M
    J Endocrinol; 1969 Jan; 43(1):iv-v. PubMed ID: 5773780
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.